— Know what they know.
Not Investment Advice

YMAB NASDAQ

Y-mAbs Therapeutics, Inc.
1W: +0.3% 1M: +1.1% 3M: +74.3% 1Y: -35.0% 3Y: -47.2% 5Y: -79.7%
$8.61
Last traded 2025-09-16 — delisted
NASDAQ · Healthcare · Biotechnology · $391.2M mcap · 34M float · 2.62% daily turnover · Short 55% of daily vol

Balance Sheet Trends

Total Assets
$120M -6.2% ▼
5Y CAGR: -11.1%
Total Liabilities
$28M +3.8% ▲
5Y CAGR: +9.8%
Shareholders Equity
$92M -8.9% ▼
5Y CAGR: -14.3%
Cash & Investments
$67M -14.5% ▼
5Y CAGR: -20.2%
Total Debt
$820K -42.2% ▼
5Y CAGR: -18.1%
Net Debt
-$66M +14.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$115M$182M$106M$79M$67M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$115M$182M$106M$79M$67M
Net Receivables$0$8M$13M$22M$20M
Inventory$0$6M$7M$5M$7M
Other Current Assets$8M$7M$5M$5M$4M
Total Current Assets$122M$202M$130M$111M$99M
Property, Plant & Equip.$6M$6M$2M$2M$859K
Goodwill & Intangibles$0$2M$3M$3M$2M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$3M$3M$6M$12M$18M
Total Non-Current Assets$10M$11M$11M$17M$21M
Total Assets$132M$213M$141M$128M$120M
— Liabilities —
Accounts Payable$9M$14M$14M$6M$7M
Short-Term Debt$0$0$0$902K$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$4M$6M$2M$8M$16M
Total Current Liabilities$20M$28M$28M$20M$24M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$5M$3M$3M$6M$4M
Total Non-Current Liabilities$7M$5M$4M$7M$4M
Total Liabilities$26M$33M$32M$27M$28M
— Equity —
Common Stock$4K$4K$4K$4K$4K
Retained Earnings-$285M-$340M-$436M-$457M-$487M
Accumulated OCI-$526K$1M$1M$449K$2M
Total Stockholders Equity$106M$180M$109M$101M$92M
Total Liabilities & Equity$132M$213M$141M$128M$120M
— Key Metrics —
Total Debt$4M$4M$2M$1M$820K
Net Debt-$111M-$178M-$104M-$77M-$66M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms